Cat. No. | Product name | CAS No. |
DCC3629 |
Neu-730
Novel inhibitor of TbrPDEB1, showing modest inhibition of T. brucei proliferation |
1622300-88-2 |
DCC3630 |
Neurodazole
Novel neurogenic inducer for converting pluripotent P19 cells into electrophysiologically active neurons |
|
DCC3631 |
Neuroprotectant-7
Novel neuroprotectant for Alzheimers disease, showing significant neuroprotection and antioxidative properties, crossing the blood-brain barrier (BBB) |
1610504-84-1 |
DCC3632 |
Neurotensin(8-13)
The neurotensin active fragment, eliciting behavioral responses typical of clinically used antipsychotic drugs when administered directly to the brain |
60482-95-3 |
DCC3633 |
Nexturastat A-crbn-12d
Novel potent HDAC6 degrader with promising antiproliferation activity in multiple myeloma (MM) cells |
|
DCC3634 |
Nfat-133
Inhibitor of NFAT-mediated transcription, leading to the suppression of interleukin-2 expression and T cell proliferation, showing immunosuppressive, antidiabetic, and antitrypanosomal activities |
|
DCC3635 |
Nf-kappab Inhibitor-2
First-in-class inhibitor of NF-κB signaling pathway by preventing the maturation of a rate-limiting multiprotein complex necessary for IKK activation |
|
DCC3636 |
N-formyl-met-phe
Neutrophil Dysfunction Test Peptide |
22008-60-2 |
DCC3637 |
Nfu1827
Novel inhibitor of human cytomegalovirus (HCMV) infection |
|
DCC3638 |
Ngd 98-2
New generation, topology 2 selective orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist |
355836-54-3 |
DCC3639 |
Ngd-8243
Novel TRPV1 Antagonist |
573678-04-3 |
DCC3640 |
Ngd9002
New generation, topology 2 selective corticotropin releasing factor-1 (CRF-1) receptor antagonist |
666256-06-0 |
DCC3641 |
Ngp1-01
Brain-permeable dual blocker of neuronal voltage- and ligand-operated calcium channels, acting as chemosensitizer and circumvent the resistance of the plasmodia parasite against chloroquine (CQ) by inhibiting the p-glycoprotein efflux pump and enabling th |
33226-57-2 |
DCC3642 |
Nh2-bodipy
Novel cell-permeant probe for the super-resolution imaging of the endoplasmic reticulum in live cells |
|
DCC3643 |
Nh2-nplh2
Novel luciferin analog, enabling both sensitive and highly resolved imaging in vivo |
1629640-37-4 |
DCC3644 |
Nh2-uamc1110
UAMC1110 Conjugate Linker |
|
DCC3645 |
Nhi-1j
Selective Inhibitor of Human Lactate Dehydrogenase Isoform A (LDH-A) |
1269802-68-7 |
DCC3646 |
Nicodicosapent
Novel inhibitor of the sterol regulatory element binding protein (SREBP) |
1269181-69-2 |
DCC3647 |
Nicofibrate
Antilipidemic agent |
31980-29-7 |
DCC3648 |
Nifrofam
Novel fluorescent probe for imaging α4β2* nAChRs |
|
DCC3649 |
Nik-21273
Potent and selective NOP receptor antagonist |
|
DCC3650 |
Nim811
Cyclophilin inhibitor, showing reduction in interleukin-2 expression and reduction in CNS inflammatory infiltrates, inhibiting HCoV-229E replication |
143205-42-9 |
DCC3651 |
Ningetinib Tosylate
Novel potent tyrosine kinase inhibitor (TKI), targeting c-Met, VEGFR2 and Axl |
1394820-77-9 |
DCC3652 |
Niraparib R-enantiomer
Novel potent PARP1 inhibitor |
1038915-58-0 |
DCC3653 |
Nir-bg2
Novel self-immobilizing near-infrared (NIR) fluorogenic probe that can be activated by senescence-associated ß-galactosidase (SA-ß-Gal), the most widely used senescence marker |
|
DCC3654 |
Nir-hs
Novel highly selective and sensitive near-infrared fluorescent probe for imaging of hydrogen sulphide in living cells and mice |
|
DCC3655 |
Nir-ii Fluorophore-h1
Novel precursor of bright-emission NIR-II fluorophores for in vivo tumor imaging and image-guided surgery |
|
DCC3656 |
Nirluc2
NIR emitting firefly luciferin analogue, displaying dose-independent improved NIR emission even at low concentrations where the native d-luciferin substrate does not emit |
|
DCC3657 |
Nir-o2
Novel NIR NIR O2˙– probe, displays superior sensitivity to NIR O2˙– and having the capability to monitor trace amounts of intracellular NIR O2˙– in AKI in vivo |
|
DCC3658 |
Nitd008
Antiviral agent against KFDV, AHFV, OHFV, as well as tick-borne encephalitis virus (TBEV) and mosquito-borne flaviviruses |
1044589-82-3 |
DCC3659 |
nitro-r-flurbiprofen
Selective modulator of amyloid-beta peptide degradation, regulating Abeta levels |
1374330-95-6 |
DCC3660 |
Nivocasan
Novel pan-caspase inhibitor, potently reducing not only inflammasome-mediated interleukin-1β (IL-1β) secretion but also osteoclast differentiation in BMMs |
908253-63-4 |
DCC3661 |
Nizofenone Fumarate
Neuroprotective, protecting neurons from death following cerebral anoxia (interruption of oxygen supply to the brain). |
54533-86-7 |
DCC3662 |
Nktr-102
Topoisomerase I inhibitor prodrug, slowly hydrolyzing and releasing irinotecan, increasing drug penetration into tumors and decreasing drug clearance |
848779-32-8 |
DCC3663 |
Nld-22
Novel Enterovirus 71 Inhibitor, binding to the hydrophobic pocket in VP1 to block viral infection, exhibiting excellent antiviral activity (with an EC50 of 5.056 nM and a 100% protection rate for mice at a dose of 20 mg/kg) and low toxicity |
|
DCC3664 |
Nlrp3 Inhibitor 4b
Novel NLRP3 inhibitor, reducing caspase-1 activation, oligomerization of ASC, and therefore, IL-1β processing, showing a significant anti-inflammatory effect and reduced mechanical hyperalgesia at 3 and 10 mg/kg (i.p.) in an in vivo mouse of gout |
|
DCC3665 |
Nmac24
Novel Nm23-H1 activator, exerting cytotoxic effects on metastatic breast cancer cells by inducing mitochondrial dysfunction only under glucose starvation |
|
DCC3666 |
nmda167-3
Novel inhibitor of the Gli1 transcription, inducing apoptosis in cancer cells but not in non-cancerous cells |
1239447-58-5 |
DCC3667 |
Nmda298-1
Novel inhibitor of glioma-associated oncogene homologue 1 (Gli1) mediated transcription |
|
DCC3668 |
Nmdi14
Novel Inhibitor of Nonsense-Mediated RNA Decay, Suppressing Nonsense p53 Mutations |
307519-88-6 |
DCC3669 |
N-me-aminopyrimidinone 9
Potent and state-dependent Nav1.7 antagonist |
1356834-62-2 |
DCC3670 |
Nmi801
Novel Mdm2 inhibitor, acting as a negative regulator of p53, reducing viability in cell culture and suppressing tumor growth |
|
DCC3671 |
nmk-td-100
Novel Microtubule Modulator, Blocking Mitosis and Inducing Apoptosis in HeLa Cells by Binding to Tubulin |
1252802-38-2 |
DCC3672 |
nms859
Covalent and allosteric inhibitor of the ATPase VCP/p97, inducing cancer cell death |
1449236-96-7 |
DCC3673 |
Nms-p715 Analog
Novel selective and orally bioavailable MPS1 inhibitor |
1202055-34-2 |
DCC3674 |
Nms-p953
Novel JAK2 inhibitor, displaying significant tumor growth inhibition in SET-2 xenograft tumor model, with a mechanism of action confirmed in vivo by typical modulation of known biomarkers, and with a favorable pharmacokinetic and safety profile |
1403679-33-3 |
DCC3675 |
Nn9056
Novel Potent and Highly Selective, Long-Acting, Peptide-Based Cholecystokinin 1 Receptor (CCK-1R) Agonist |
|
DCC3676 |
N-n-butyl Haloperidol Iodide
Novel inhibitor of autophagy, protecting cardiomyocytes against hypoxia/reoxygenation injury |
|
DCC3677 |
Nnc-38-1049
Novel selective histamine H3 antagonist |
757183-18-9 |
DCC3678 |
Nn-dnj
Iminosugar, binding to the active site of lysosomal beta-glucosidase and stabilizing the proper folding for the catalytic form, acting as a chemical chaperone that facilitate transport and maturation of acid beta-Glu |
81117-35-3 |
DCC3679 |
Nnmt Inhibitor Ns1
Novel potent alkynyl bisubstrate inhibitor of nicotinamide N-methyltransferase (NNMT) |
|
DCC3680 |
nnrti F2
Novel non-nucleoside reverse transcriptase inhibitor (NNRTI) |
1152034-94-0 |
DCC3681 |
Nocardicin A
Moderate antibiotic agent against a broad spectrum of gram-negative bacteria |
39391-39-4 |
DCC3682 |
Nocardicin G
The universal precursor of the nocardicins |
65309-11-7 |
DCC3683 |
Nocathiacin I
Natural Inhibitor of an Oncogenic RNA, targeting RNA folds in the nuclease processing site in the oncogenic, noncoding microRNA-18a, selectively inhibiting nuclease processing in vitro and in prostate cancer cells and triggering apoptosis |
214044-52-7 |
DCC3684 |
nocazine C
Nocazine family member |
1421460-89-0 |
DCC3685 |
nocazine E
Marine natural nocazine family member; Standard used in nocazine biosynthetic parthway studies |
1421460-90-3 |
DCC3686 |
Nociceptin
Neuropeptide, acting as a endogenous ligand for the nociceptin receptor (NOP, ORL-1) |
170713-75-4 |
DCC3687 |
N-oleoylethanolamine
PPARalpha agonist and EC 3.5.1.23 (ceramidase) inhibitor |
111-58-0 |
DCC3688 |
Nomegestrol
Steroidal progestin |
58691-88-6 |
DCC3689 |
Nomegestrol Acetate
Neutral, nonandrogenic, progesterone-like profile progestin |
58652-20-3 |
DCC3690 |
Nonoxynol-9
Novel human epidermal growth factor receptor-2 (HER2) inhibitor; Spermatocide |
26571-11-9 |
DCC3691 |
Nord-1
Novel red-light-controllable nitric oxide (NO) releaser |
|
DCC3692 |
Nor-fauc-365
FAUC-365 analog |
|
DCC3693 |
Norgestomet
Steroidal progestin used in veterinary medicine to control estrus and ovulation in cattle |
25092-41-5 |
DCC3694 |
Noricumazole A
Secondary metabolite from the myxobacterium Sorangium cellulosum, acting as a potent HCV inhibitor, Ebola virus (EBOV) entry inhibitor, and a potassium channel inhibitor |
|
DCC3695 |
No-rosa5
Controllable nitric oxide (NO) donor, releasing NO triggered by photoinduced electron transfer (PeT) |
|
DCC3696 |
Noscapine
Natueal sigma receptor agonist, attenuating cytokine release associated with SARS-CoV-2, also being used as anti-malarial, anti-stroke and cough-suppressant |
128-62-1 |
DCC3697 |
Notum-in-23dd
Novel potent inhibitor of notum carboxylesterase activity |
|
DCC3698 |
Notum-in-24
Novel potent notum inhibitor (OPTS IC50 3.6nM; TCF-LEF EC50 220nM), showing good plasma exposure and reasonable CNS penetration |
|
DCC3699 |
Nov-lrrk2-11
Novel potent LRRK2 inhibitor |
|
DCC3700 |
Novolactone
Natural inhibitor of the allosteric regulation of Hsp70 |
1804950-46-6 |
DCC3701 |
Np-005497
Natural inhibitor of jasmonate signaling targets JAR1 in Arabidopsis thaliana |
|
DCC3702 |
Npa101.3
Second-Generation RET/VEGFR2 Inhibitor |
1839155-15-5 |
DCC3703 |
Np-c86
Novel stabilizer of long noncoding RNA (lncRNA) GAS5, binding to GAS5 with high affinity, and increasing GAS5 levels and glucose uptake in diabetic patient adipocytes |
|
DCC3704 |
Npd-008
Novel Inhibitor of Trypanosoma brucei Phosphodiesterase B1 (TbrPDEB1) |
2229043-42-7 |
DCC3705 |
Npd-039
Novel Inhibitor of Trypanosoma brucei Phosphodiesterase B1 (TbrPDEB1) |
2229043-40-5 |
DCC3706 |
Npd-048
Novel inhibitor of Trypanosoma brucei PDEB1 (TbrPDEB1) |
|
DCC3707 |
Npd11033
Novel selective SIRT2 inhibitor, creating a hydrophobic cavity behind the substrate-binding pocket after a conformational change of the Zn-binding small domain of SIRT2 |
|
DCC3708 |
Npd12671
Novel activator of 15-ADON production, significantly increasing the transcription of Tri6, a transcription factor gene necessary for trichothecene biosynthesis, in both trichothecene-inducing and noninducing culture conditions |
865282-76-4 |
DCC3709 |
Npd2639
Novel biomediator, inducing reveromycin production in Streptomyces sp. SN-593 |
859130-76-0 |
DCC3710 |
Npd6689
Novel tubulin inhibitor |
859671-40-2 |
DCC3711 |
Npd7155
Novel competitive MTH1 inhibitor |
924764-38-5 |
DCC3712 |
Npd8617
Novel tubulin inhibitor |
313481-28-6 |
DCC3713 |
Npd9055
Novel heterotrimeric G-protein Gi modulator, inhibiting GDP/GTP exchange on a Gαi subunit induced by a G-protein-coupled receptor agonist, but not on another G-protein from the Gαs family, regulating Gβγ-dependent cellular processes, most likely by causin |
327102-63-6 |
DCC3714 |
Nplc0393
Novel inhibitor of TGF-β1 signaling pathway, inhibiting the upregulation of MAT2A mechanistically, dose-dependently activating PP2Cα and efficiently alleviating liver fibrosis |
862286-45-1 |
DCC3715 |
Npr-c Activator 1
Novel potent activator of the natriuretic peptide receptor C (NPR-C) with EC 50 ~1 μM |
|
DCC3716 |
Nps-89636
Calcilytic negative allosteric modulator of calcium-sensing receptor (CaR) |
1588949-48-7 |
DCC3717 |
Nqo1 Substrate 1
Novel substrate for NAD(P)H: quinone oxidoreductase 1 (NQO1), acting as an effective intracellular ROS generator for the treatment of drug-resistant non-small-cell lung cancer |
2304503-05-5 |
DCC3718 |
Nr2b-in-1
Novel NMDA/NR2B Antagonist |
913574-42-2 |
DCC3719 |
Nrf2/ho-1 Activator Ll202
Novel activator of the Nrf2/HO-1 pathway, upregulating heme oxygenase-1 (HO-1) via promoting nuclear translocation of nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) to regulate LPS‐induced oxidative stress in macrophages |
|
DCC3720 |
Nrf2-activator
Featured
Nrf2-Activator is a potent Nrf-2 activator. |
1554271-18-9 |
DCC3721 |
Ns-0011
Novel inhibitor of CDK5 translocation, increasing CDK5 accumulation in the nucleus, suppressing both cancer cell proliferation and xenograft tumorigenesis. |
1076234-33-7 |
DCC3722 |
Ns-2710
Potent, non-selective partial agonist at GABAA receptors with little efficacy at the alpha1 subtype and more at alpha2 and alpha3 |
184220-36-8 |
DCC3723 |
ns3/4a-in-12
Novel Inhibitor with Activity against NS3/4A proteases from Multiple Hepatitis C Virus Genotypes |
|
DCC3724 |
ns3-in-5
Novel allosteric inhibitor of HCV NS3 protein function |
1434713-38-8 |
DCC3725 |
Ns4591
Novel molulator of SK-IK channels [small- and intermediate-conductance Ca2(+) -activated K(+) channels] |
273930-52-2 |
DCC3726 |
Ns-6740
Novel potent α7 nAChR partial agonist |
753499-14-8 |
DCC3727 |
Ns-6784 Hydrochloride
Novel α7 nAChR agonist at human and rat receptors |
677723-97-6 |
DCC3728 |
Nsc10010
Novel potent growth inhibitor for gammaherpesvirus-associated B-lymphomas through activation of both the NF-κB and c-Myc-mediated signaling pathways |
6286-09-5 |
DCC3729 |
Nsc1008
Novel Inhibitor of the Ras Converting Enzyme 1 (Rce1) Protease, Disrupting Ras Membrane Localization in Human Cells |
5335-95-5 |
DCC3730 |
Nsc-100874
Novel antagonist of the Grb7 SH2 domain; Antitumor Agent |
1135059-20-9 |
DCC3731 |
Nsc1011
Ras converting enzyme 1 (Rce1) inhibitor |
5335-97-7 |
DCC3732 |
Nsc103054
Novel inhibitor of ABCG2 transporter function |
19590-55-7 |
DCC3733 |
Nsc-104999
Ligand of the Grb7 SH2 domain, inhibiting the growth of MDA-MB-468 cancer cells |
1118745-14-4 |
DCC3734 |
Nsc107392
Novel substrate of ABCG2 |
19494-89-4 |
DCC3735 |
Nsc109131
Inhibitor of human tyrosyl-DNA phosphodiesterase 1 (TDP1) |
21170-27-4 |
DCC3736 |
Nsc109779
Novel potent inhibitor of Huntington's disease (HD) pathogenesis via targeting CAG repeats RNA and Poly Q protein |
|
DCC3737 |
Nsc114792
Novel selective inhibitor of JAK3 |
17392-79-9 |
DCC3738 |
Nsc-117199
Selective inhibitor of shp2 protein tyrosine phosphatase (PTP) |
21303-44-6 |
DCC3739 |
Nsc-12404
Selective non-lipid agonist of LPA2/3 |
5411-64-3 |
DCC3740 |
Nsc-126188
Apoptosis inducer; Antitumor agent |
31863-82-8 |
DCC3741 |
Nsc127133
Novel inhibitor of the second bromodomain (BD2) of the BET family protein BRD2 |
|
DCC3742 |
Nsc-13030
Novel potent SHP2 Inhibitor with Anti-Proliferative Activity in Breast Cancer Cell Lines |
5442-51-3 |
DCC3743 |
Nsc-134754
HIF-pathway inhibitor |
75041-32-6 |
DCC3744 |
Nsc13987
Novel inhibitor of Nef-calnexin interaction |
81-94-7 |
DCC3745 |
Nsc-140873
Inhibitor of the RUNX1-CBFβ interaction |
106410-13-3 |
DCC3746 |
Nsc16168
Specific inhibitor of ERCC1-XPF with no effect on both HhaI and XPG |
6837-93-0 |
DCC3747 |
Nsc175176
Novel potent and selective serotonin reuptake inhibitor (SSRI) |
|
DCC3748 |
nsc-176327
Selective G-quadruplex inducer of the human telomeric sequence; Stabilizer of the G-quadruplex formed by the MYC promoter sequence; Anti-neoplastic effects in wild-type p53, p53-mutant or p53-deficient human colon cancer cells. |
85632-83-3 |
DCC3749 |
Nsc-176377
Non-nucleoside reverse transcriptase inhibitor |
20841-26-3 |
DCC3750 |
Nsc-18725
Novel inhibitor of growth of intracellular Mycobacterium tuberculosis, inducing autophagy in differentiated THP-1 macrophages |
715-99-1 |
DCC3751 |
nsc-20596
Capturer of kinase-insertion domain receptor (KDR) from a solution, while allowing the captured KDR to bind with the solution-phase vascular endothelial growth factor (VEGF) |
6976-14-3 |
DCC3752 |
Nsc24048
Novel inhibitor of ABCG2 transporter function |
5459-47-2 |
DCC3753 |
Nsc-24198
Novel potent SHP2 Inhibitor with Anti-Proliferative Activity in Breast Cancer Cell Lines |
7152-78-5 |
DCC3754 |
Nsc24674
Novel 3C-like protease inhibitor of SARS-CoV-2 |
|
DCC3755 |
Nsc-2488 [5459-61-0]
Novel Rho-Kinase-II Inhibitor with Vasodilatory Activity |
5459-61-0 |
DCC3756 |
nsc-252359
Specific Ligand for Stem Loop 3 Ribonucleic Acid of the Packaging Signal Ψ of Human Immunodeficiency Virus-1 |
500889-59-8 |
DCC3757 |
Nsc265473
Novel substrate of ABCG2 |
61786-74-1 |
DCC3758 |
Nsc-279287
Novel Inhibitor of the p53-mdm2 Interaction, Activating p53-Dependent Transcription in mdm2-Overexpressing Cells |
59541-35-4 |
DCC3759 |
Nsc-2888
Novel Rho-Kinase-II Inhibitor with Vasodilatory Activity |
5335-14-8 |
DCC3760 |
Nsc-299202
Novel potent gonist of Human G Protein-Coupled Receptor-35 (hGPR35) (EC50 8 nM) |
49635-47-4 |
DCC3761 |
Nsc30049
Novel inhibitor of Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations |
|
DCC3762 |
Nsc-311068
Novel selective inhibitor of TET1 transcription and 5-hydroxymethylcytosine (5hmC) modification, effectively inhibiting cell viability in AML with high expression of TET1 |
73768-68-0 |
DCC3763 |
Nsc-33353
Potent inhibitor of the AcrAB-TolC efflux pump in Escherichia coli, potentiating the antibacterial activities of novobiocin and erythromycin upon binding to the membrane fusion protein AcrA |
|
DCC3764 |
Nsc-339579
Novel potent Mycobacterium tuberculosis DHFR inhibitor |
65795-53-1 |
DCC3765 |
Nsc339614 Potassium Salt
Selective potentiator at GluN1/GluN2C and GluN1/GluN2D receptors |
1135037-53-4 |
DCC3766 |
Nsc-347518
DT-diaphorase inhibitor |
87626-58-2 |
DCC3767 |
Nsc-4231
Novel Rho-Kinase-II Inhibitor with Vasodilatory Activity |
5397-55-7 |
DCC3768 |
nsc48693 Dihydrochloride
Potent apoptosis inducer in pancreatic cancer cells |
1356084-90-6 |
DCC3769 |
Nsc52101
Novel potent inhibitor of Huntington's disease (HD) pathogenesis via targeting CAG repeats RNA and Poly Q protein |
|
DCC3770 |
Nsc-55158
Novel antagonist of the Grb7 SH2 domain; Antitumor Agent |
5507-11-9 |
DCC3771 |
Nsc56452
Novel specific inhibitor of EGF receptor autophosphorylation and cell proliferation in HeLa cells by disrupting allosteric activation of EGF-stimulated dimer |
|
DCC3772 |
Nsc-57148
Novel antagonist of the Grb7 SH2 domain; Antitumor Agent |
4315-44-0 |
DCC3773 |
Nsc-57774
Novel potent SHP2 Inhibitor with Anti-Proliferative Activity in Breast Cancer Cell Lines |
524-11-8 |
DCC3774 |
Nsc57971
Novel non-peptide disruptor of IKKß/NEMO complex |
6632-11-7 |
DCC3775 |
Nsc-60339
Novel efflux pump inhibitor (EPI) |
70-09-7 |
DCC3776 |
Nsc61610
Novel activator of lanthionine synthetase C-like 2 (LANCL2), down-modulating pulmonary inflammation through the downregulation of TNF-α and MCP-1 and reduction in the infiltration of neutrophils, accelerating recovery and inducing IL-10-mediated regulator |
500538-94-3 |
DCC3777 |
Nsc-627757
Novel DNA repair inhibitor |
|
DCC3778 |
Nsc636795
Novel inhibitor of ABCG2 transporter function |
66528-28-7 |
DCC3779 |
Nsc-657186
Novel selective non-zinc-binding MMP-2 inhibitor |
1772-39-0 |
DCC3780 |
Nsc65847
Novel dual inhibitor of viral and Streptococcus pneumoniae neuraminidase |
6949-15-1 |
DCC3781 |
Nsc66098
Novel potent inhibitor of Huntington's disease (HD) pathogenesis via targeting CAG repeats RNA and Poly Q protein |
3259-43-6 |
DCC3782 |
Nsc663627
IκBα phosphorylation inhibitor |
51837-75-3 |
DCC3783 |
Nsc-670224
Toxitant of Saccharomyces_cerevisiae>Saccharomyces cerevisiae |
1374648-47-1 |
DCC3784 |
Nsc-672121
Potent CDC25A>Cdc25A inhibitor; Vitamine K3 analogue |
59147-84-1 |
DCC3785 |
Nsc-674205
Potent and selective nociceptin opioid receptor (NOP) agonist |
13130-47-7 |
DCC3786 |
Nsc676914a
Novel NF-κB inhibitor |
|
DCC3787 |
nsc-681152
Novel inhibitor of the Skp2-Cks1 protein-protein interaction and p27(Kip1) ubiquitination in vitro |
241128-06-3 |
DCC3788 |
Nsc-689857
Novel inhibitor of the Skp2-Cks1 protein-protein interaction and p27Kip1 ubiquitination in vitro |
241127-79-7 |
DCC3789 |
Nsc704342
Novel Inhibitor of HCV NS3/4A Proteinase |
|
DCC3790 |
Nsc705841
Novel selective serotonin reuptake inhibitor (SSRI), exhibiting higher binding affinities in comparison with the paroxetine |
|
DCC3791 |
Nsc724526
Novel Inhibitor of HCV NS3/4A Proteinase |
|
DCC3792 |
Nsc724527
Novel Inhibitor of HCV NS3/4A Proteinase |
|
DCC3793 |
Nsc-73306
Cytotoxic MDR-selective ligand |
79560-74-0 |
DCC3794 |
Nsc-741909
Novel anticancer agent, suppressing the growth of several cell lines derived from lung, colon, breast, ovarian, and kidney cancers |
92407-91-5 |
DCC3795 |
Nsc745885
Novel down-regulator of EZH2, inducing G2/M cell-cycle arrest of cancer cells and degradating p53 via proteasome-dependent and -independent pathways |
4219-52-7 |
DCC3796 |
nsc746364
Telomerase inhibitor, stabilizing G-quadruplex and suppressing cell growth of A549 human lung cancer cells through activation of the ATR/Chk1-dependent pathway |
1190593-30-6 |
DCC3797 |
nsc746365 Maleate
Telomerase inhibitor, anticancer agent |
209176-53-4 |
DCC3798 |
Nsc747854
Novel inhibitor of poly (ADP-ribose) polymerase-1 (PARP-1) |
1329520-12-8 |
DCC3799 |
Nsc750212
Novel inhibitor of lipid metabolism, disrupting tubulin polymerization,suppressing monoglycerol metabolism depleting lipids and inhibiting the growth of both lymphoma and RCC both in vitro and in vivo |
|
DCC3800 |
Nsc-77053
The first reported BoNT/E small molecule inhibitor |
77308-57-7 |
DCC3801 |
Nsc-79887
Novel inhibitor of nucleoside hydrolase (NH) |
19056-78-1 |
DCC3802 |
Nsc-80141
Selective inhibitor of HsEg5 |
97027-56-0 |
DCC3803 |
Nsc-84096
Potent inhibitor of endopeptidase activity of botulinum neurotoxin type A light chain (rBoNT/A-LC) |
908813-78-5 |
DCC3804 |
Nsc-8891
Tyrosyl-DNA phosphodiesterase (Tdp1) inhibitor |
21170-34-3 |
DCC3805 |
Nsc-9037
First-in-class probe of Rad6 function, inhibiting Rad6 function and Rad6-Rad18 interaction in the PCNA ubiquitination cascade |
3569-82-2 |
DCC3806 |
nsc-96626
Novel B-Raf(V600E) inhibitor |
27430-18-8 |
DCC3807 |
Nsi-189 Phosphate
Novel stimulator of neurogenesis of human hippocampus-derived neural stem cells in vitro and in vivo. |
1270138-41-4 |
DCC3808 |
Nsmase2-in-1
Novel inhibitor of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases |
|
DCC3809 |
Nsp-116
Novel free radical scavenger, against light-induced photoreceptor cell damage |
|
DCC3810 |
Nti-007
Potent anti-HBV agent, targeting the NTCP-APOA1-HBx-Beclin1-mediated autophagic pathway |
|
DCC3811 |
Ntrc-739
Novel nonpeptide selective ligand for NTS2 |
|
DCC3812 |
Ntrc-808
Novel nonpeptide potent and selective partial agonist of the Neurotensin receptor type 2 (NTS2) |
|
DCC3813 |
Ntrd22
Novel Allosteric Modulator of RNA Binding Targeting the N-Terminal Domain of TDP-43 |
|
DCC3814 |
Ntr-responsive Protac 17-1
The first NTR-responsive PROTAC, incorporating the caging group on the Von Hippel-Lindau (VHL) E3 ubiquitin ligase ligand, efficiently degrading the EGFR protein and subsequently exert antitumor efficacy |
|
DCC3815 |
Ntz-15
Novel potent STAT3 inhibitor, exhibiting much improved in vivo pharmacokinetic parameters in rats and efficacies against proliferations in multiple cancer cell lines |
|
DCC3816 |
Ntz-24
Novel potent STAT3 inhibitor |
69819-42-7 |
DCC3817 |
Ntzdpa
Novel potent and selective non-thiazolidinedione partial Peroxisome_proliferator-activated_receptor>PPARγ agonist, acting as an antibiotic effectively against bacterial persisters |
118414-59-8 |
DCC3818 |
Nu6155
Novel potent CDK2 inhibitor |
|
DCC3819 |
Nuc013
Novel DNA methytransferase inhibitor, be significantly safer and more effective than decitabine in xenograft models of human leukemia and colon cancer |
|
DCC3820 |
Nucc-201177
Novel highly potent and selective MEK4 inhibitor |
|
DCC3821 |
Nucc-474
Novel potent activin antagonist |
|
DCC3822 |
Nucc-555
First-in-class activin antagonist, specifically binding to ALK4, which opens a completely new approach to inhibiting the activity of TGF-beta receptor superfamily members |
1060469-90-0 |
DCC3823 |
Nucleocidin
Nucleosidic antibiotic |
24751-69-7 |
DCC3824 |
Nuod-in-25
Novel inhibitor of Helicobacter pylori , targeting H. pylori's respiratory complex I subunit NuoD |
|
DCC3825 |
Nurf Inhibitor Bz1
Novel Potent Cell-Active Inhibitor of the Nucleosome Remodeling Factor (NURF) via BPTF Bromodomain Inhibition |
|
DCC3826 |
Nusb-nuse Inhibitor-22
Novel Inhibitor of the NusB-NusE Protein-Protein Interaction with Antibiotic Activity |
|
DCC3827 |
Nusb-nuse Interaction Inhibitor-1
Novel modulator of the NusB-NusE interaction |
125966-81-6 |
DCC3828 |
Nutlin-1
p53-MDM2 binding inhibitor; p-Glycoprotein (p-gp) transport substrate; Antitumer agent |
548472-58-8 |